Want to see AU:ACW full AI Analyst Report?
Top Page
Actinogen Medical
(Sydney:ACW)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.04
▲(7.50% Upside)
Action:Reiterated
Date:10/14/26
The score is primarily constrained by weak financial performance, including FY2026 revenue dropping to zero, sizable losses, and heavy cash burn. Technicals are mixed but generally soft with the stock below key short-term averages and muted momentum. Valuation offers limited support due to a negative P/E and no provided dividend yield.
Positive Factors
Lead drug candidate
A clearly defined lead program gives Actinogen a focused development strategy around one differentiated therapeutic approach. Xanamem’s oral format and targeting of Alzheimer’s disease and major depressive disorder provide identifiable clinical applications that could support future value creation if development succeeds.
Negative Factors
Revenue collapse
The disappearance of reported revenue materially weakens the company’s ability to fund operations from internally generated business activity. Without a reliable top-line stream, Actinogen remains dependent on successful clinical progress and future financing to sustain its development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Lead drug candidate
A clearly defined lead program gives Actinogen a focused development strategy around one differentiated therapeutic approach. Xanamem’s oral format and targeting of Alzheimer’s disease and major depressive disorder provide identifiable clinical applications that could support future value creation if development succeeds.
Read all positive factors
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$166.59M
Dividend YieldN/A
Average Volume (3M)4.84M
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue GrowthN/A
EPS Growth5.88%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,874,168,200
10 Day Avg. Volume4,883,425
30 Day Avg. Volume4,840,738
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)4.83
Price to Sales (P/S)0.00
P/FCF Ratio-5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$38.50M
Actinogen Medical Business Overview & Revenue Model
Company Description
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HS...
Actinogen Medical Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.49M | 9.93M | 4.89M | 3.64M |
| Gross Profit | -419.27K | 5.49M | 9.93M | 4.48M | 3.24M |
| EBITDA | -27.69M | -14.93M | -12.84M | -15.22M | -12.72M |
| Net Income | -15.38M | -14.73M | -13.04M | -10.75M | -9.50M |
Balance Sheet | |||||
| Total Assets | 29.56M | 24.48M | 21.31M | 15.21M | 23.31M |
| Cash, Cash Equivalents and Short-Term Investments | 16.73M | 16.50M | 9.45M | 8.46M | 16.37M |
| Total Debt | 4.78M | 3.26M | 319.07K | 86.93K | 165.27K |
| Total Liabilities | 8.18M | 6.15M | 1.62M | 1.80M | 1.57M |
| Stockholders Equity | 21.37M | 18.34M | 19.70M | 13.41M | 21.74M |
Cash Flow | |||||
| Free Cash Flow | -17.57M | -7.59M | -16.96M | -8.73M | -9.52M |
| Operating Cash Flow | -17.56M | -7.56M | -16.95M | -8.70M | -9.52M |
| Investing Cash Flow | -9.29K | -38.02K | -8.16K | -36.60K | -2.94K |
| Financing Cash Flow | 17.80M | 14.65M | 17.95M | 824.62K | 12.42M |
Actinogen Medical Technical Analysis
Positive
0.04
Price Trends
0.05
Negative
0.04
Positive
0.04
Positive
Market Momentum
>-0.01
Positive
45.94
Neutral
28.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.94 is Neutral, neither overbought nor oversold. The STOCH value of 28.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACW.
Actinogen Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$2.49B | 121.92 | 6.03% | 0.76% | -68.00% | -86.31% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$22.60M | -4.10 | -30.02% | ― | ― | -10.32% | |
44 Neutral | AU$166.59M | -9.79 | -103.42% | ― | ― | 5.88% | |
44 Neutral | AU$61.87M | -2.31 | -48.25% | ― | ― | -16.21% | |
43 Neutral | AU$53.93M | -13.91 | -63.60% | ― | ― | 29.55% |
* Healthcare Sector Average
AU:ACW
Actinogen Medical
0.05
0.01
34.29%
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-11.11%
AU:NEU
Neuren Pharmaceuticals Limited
19.81
-0.98
-4.70%
AU:ATH
Alterity Therapeutics
0.27
-0.29
-51.82%
AU:ZLD
Zelira Therapeutics
0.50
0.15
40.85%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.06
-0.08
-58.57%
Actinogen Medical Corporate Events
Actinogen Medical Announces Employee Share Scheme Buy-Back
Oct 12, 2026
Actinogen Medical Limited has announced an employee share scheme buy-back of its ordinary fully paid shares listed on the ASX under the ticker ACW. The move reflects the company’s ongoing management of its equity-based compensation programs ...
Actinogen Sets AGM as Pivotal Alzheimer’s Trial Nears Key Readout
Oct 8, 2026
Actinogen Medical has scheduled its Annual General Meeting for 11 a.m. on 30 November 2026 in Sydney, where the re‑election and appointment of directors will be on the agenda, and it has set 5 p.m. on 16 October 2026 as the deadline for writ...
Actinogen Medical Adds Modest Number of New Shares to ASX Listing
Sep 30, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company, has its ordinary fully paid shares quoted under the code ACW, positioning it within Australia’s public healthcare and life sciences investment landscape. The listing enables the...
Actinogen issues underwritten shortfall shares as Xanamem trials advance
Sep 23, 2026
Actinogen Medical has issued 26,315,700 fully paid ordinary shares at $0.0375 each to Forrest Capital or its nominees, covering the shortfall from previously announced unlisted options under an underwriting agreement. The company stated that these...
Actinogen Medical Seeks ASX Quotation for 26.3 Million New Shares
Sep 23, 2026
Actinogen Medical has applied to the ASX for quotation of 26,315,700 new ordinary fully paid shares, with an issue date of 23 September 2026, under its existing ticker ACW. The additional securities, issued pursuant to a previously announced trans...
Actinogen extends cash runway to 2028 after completing option underwriting
Sep 23, 2026
Actinogen Medical has completed the underwriting of options, issuing 26,315,700 shortfall shares to Forrest Capital and its nominees, raising approximately $4.77 million in additional funding without using its ASX Listing Rule 7.1 placement capaci...
Actinogen Completes Visits in Pivotal Alzheimer’s Trial Ahead of November Data
Sep 22, 2026
Actinogen Medical has completed all patient visits in its pivotal XanaMIA Phase 2b/3 trial of oral Xanamem in mild to moderate Alzheimer’s disease, confirming that topline data are scheduled for November. The study enrolled 247 patients in A...
Actinogen Medical Options Expire, Streamlining ASX-Listed Capital Structure
Sep 16, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company, has reported changes to its issued capital following the expiry of certain options. The company, identified on the market by the ticker ACW, remains active in updating investors on th...
Actinogen Medical Seeks ASX Quotation for 21.9 Million New Shares
Sep 15, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company, develops medical therapies and is funded through the issuance of ordinary fully paid shares on the Australian Securities Exchange. The company’s operations and investor base are...
Actinogen Medical Seeks ASX Quotation for 22.5 Million New Shares
Sep 11, 2026
Actinogen Medical Limited has applied to the ASX for quotation of 22,526,238 new ordinary fully paid shares under code ACW. The securities, issued on 11 September 2026, arise from the exercise or conversion of existing options or other convertible...
Actinogen Director Boosts Shareholding Through Option Exercise
Sep 9, 2026
Actinogen Medical has reported a change in the equity interests of director Dr Geoffrey Brooke, reflecting movements in his direct and indirect holdings in the company’s shares and options. The disclosure details his positions in fully paid ...
Actinogen Medical Expands ASX-Quoted Share Base
Sep 9, 2026
Actinogen Medical Limited, a biotechnology company listed on the ASX under the code ACW, focuses on developing medical treatments and relies on equity markets to support its research and development programs. Its ordinary fully paid shares are the...
Actinogen Showcases Cortisol-Targeting Alzheimer’s Drug Ahead of Key Trial Readout
Sep 9, 2026
Actinogen Medical has built its pipeline around Xanamem, a once-daily, brain-penetrant 11β-HSD1 inhibitor designed to normalize cortisol levels in key brain regions implicated in Alzheimer’s disease and mood disorders. The company has a...
Actinogen Medical Seeks ASX Quotation for 8 Million New Shares
Sep 8, 2026
Actinogen Medical has applied to the ASX for quotation of 8,000,000 ordinary fully paid shares, to be issued on September 8, 2026. The securities stem from an employee incentive scheme, signalling ongoing use of equity-based compensation and a mod...
Actinogen Medical Expands ASX-Quoted Share Capital
Sep 7, 2026
Actinogen Medical Limited has lodged a new application with the ASX for quotation of additional ordinary fully paid shares. The filing details the issue and quotation of 17,202,872 ACW securities dated September 7, 2026, expanding the company̵...
Actinogen Medical Seeks ASX Quotation for 11.9 Million New Shares
Sep 3, 2026
Actinogen Medical has applied to the ASX for quotation of 11,875,155 new ordinary fully paid shares, expanding its listed security base under the ticker ACW. The issuance of these additional securities increases the company’s share capital a...
Actinogen Plans Major Share Placement to Bolster Funding Capacity
Sep 1, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the code ACW, develops medical treatments and leverages capital markets to support its research and corporate growth. The company issues ordinary fully paid shares to inv...
Actinogen secures full underwriting of $4.77m options to extend Xanamem funding runway
Sep 1, 2026
Actinogen Medical has secured full underwriting of its remaining unlisted options, valued at about $4.77 million, from long-term shareholder Forrest Capital, bolstering funding for its late-stage neurology pipeline. The company’s pivotal Xan...
Actinogen Medical Seeks ASX Quotation for 3.6 Million New Shares
Aug 28, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 3,582,562 new ordinary fully paid shares, to be issued on 28 August 2026 under its ACW ticker. The move increases the company’s quoted share capital and reflects the conversio...
Actinogen director increases shareholding through option exercise
Aug 28, 2026
Actinogen Medical has reported a change in director Dr George Morstyn’s interests, following the exercise of unlisted options into fully paid ordinary shares. The transaction involved converting 307,269 unlisted options, exercisable at $0.03...
Actinogen Director Increases Equity Stake Through Option Exercise
Aug 28, 2026
Actinogen Medical has disclosed a change in interests held by director Dr Geoffrey Brooke, following the exercise of previously granted unlisted options. Dr Brooke converted 275,331 unlisted options into an equal number of fully paid ordinary shar...
Actinogen Medical Seeks ASX Quotation for 6.9 Million New Shares
Aug 28, 2026
Actinogen Medical has applied for quotation on the ASX of 6,866,235 additional ordinary fully paid shares, with an issue date of August 28, 2026. The new securities arise from the exercise or conversion of existing options or other convertible ins...
Actinogen Medical Updates Corporate Governance Framework to Align with ASX Standards
Aug 27, 2026
Actinogen Medical has issued an updated Corporate Governance Statement outlining how its board manages and oversees the company on behalf of shareholders. The statement confirms adoption, where practical for its size and nature, of the ASX Corpora...
Actinogen readies pivotal Alzheimer’s data as R&D spend climbs
Aug 27, 2026
Actinogen has reported its FY2026 results, highlighting that its pivotal XanaMIA trial in Alzheimer’s disease remains on track for topline data in November following positive independent monitoring reviews. The company also commenced an open...
Actinogen Director Boosts Shareholding Through Option Exercise
Aug 20, 2026
Actinogen Medical has reported a change in director interests following the exercise of options by board member Dr George Morstyn. The transaction involved converting 299,805 unlisted options into fully paid ordinary shares, modestly increasing hi...
Actinogen Medical Seeks ASX Quotation for 5.9 Million New Shares
Aug 20, 2026
Actinogen Medical Limited has lodged a new application with the ASX for the quotation of additional ordinary fully paid shares. The filing covers 5,914,852 ACW securities, which are to be admitted to trading as part of the company’s existing...
Actinogen Director McComas Exercises Options to Boost Shareholding
Aug 17, 2026
Actinogen Medical has reported changes in the relevant interests of director Malcolm McComas following the exercise of unlisted options. Through related entities Bunyula Super Pty Ltd and McComas Capital Pty Ltd, McComas converted a total of 200,6...
Actinogen Medical Seeks ASX Quotation for 3.2 Million New Shares
Aug 17, 2026
Actinogen Medical has applied to the Australian Securities Exchange for quotation of 3,198,135 new ordinary fully paid shares, issued on 17 August 2026. The securities result from the exercise or conversion of existing options or other convertible...
Actinogen steps up Alzheimer’s push with expert science forum as key Xanamem trial nears data
Aug 11, 2026
Actinogen Medical will host a Clinical Trials Science Forum webinar today, featuring leading Alzheimer’s experts to discuss evolving diagnostic and treatment paradigms, real-world experience with anti-amyloid drugs, and physician expectation...
Actinogen Medical Tightens Trading Rules With New Governance Policy
Aug 10, 2026
Actinogen Medical has adopted a Securities Trading Policy that sets out when directors, senior management and employees may trade in the company’s securities and in securities of other listed entities. The policy reinforces that trading rule...
Actinogen Medical Seeks ASX Quotation for Additional Shares
Aug 10, 2026
Actinogen Medical Limited has applied for quotation of an additional 41,014 ordinary fully paid shares on the ASX. The new securities, with issuer code ACW, are scheduled to be issued on August 10, 2026.The modest increase in quoted shares reflect...
Actinogen Medical Cancels 1.67 Million Shares Under Employee Buy-Back
Aug 9, 2026
Actinogen Medical has announced the cessation of 1,666,666 ordinary fully paid shares following their cancellation under an employee share scheme buy-back. The adjustment to its issued capital reflects routine management of equity-based compensati...
Actinogen Medical Seeks ASX Quotation for 3.5 Million Incentive Shares
Aug 5, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the ticker ACW, operates in the healthcare and life sciences sector, offering exposure to investors seeking innovative medical development plays. Its ordinary fully paid ...
Actinogen to Host Alzheimer’s Treatment Forum as Xanamem Program Advances
Aug 5, 2026
Actinogen Medical will host a Clinical Trials Science Forum webinar on 12 August to explore the future of Alzheimer’s diagnosis and treatment with leading specialists, including its Chief Medical Officer and internationally recognized neurol...
Actinogen advances pivotal Alzheimer’s trial as regulatory pathway and cash runway strengthen
Jul 30, 2026
Actinogen Medical reported steady progress in its pivotal XanaMIA phase 2b/3 trial in Alzheimer’s disease, which remains fully enrolled and on track for topline results in November, supported by a third positive safety recommendation from th...
Actinogen Medical Seeks ASX Quotation for New Share Issue
Jul 28, 2026
Actinogen Medical Limited has applied to the Australian Securities Exchange for quotation of 340,002 new ordinary fully paid shares under the code ACW. The securities, issued on 28 July 2026, arise from the exercise of options or conversion of oth...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.